Pharma Update
Growing portfolio in breast cancer: Expanding beyond HER2+ BC
Breast cancer cases by subtype¹
Ph III clinical development overview
On-market portfolio
Pipeline molecules
Phl
|
Ph II
|
Ph III
Herceptin
giredestrant
(SERD)
69%
PERJETA
pertuzumab
PHESGO®
PERTUZUMAB-TRASTUZUMAB
>Kadcyla
ado-trastuzumab emtansine
for injection
10%
"TECENTRIQ
10%
atezolizumab
4%
7%
inavolisib
(PI3Ka inhibitor)
runimotamab
(HER2xCD3)
ZN-1041
(HER2 TKI)
Giredestrant + palbociclib (perservERA) in 1L ER+/HER2- MBC
Giredestrant + CDK4/6 (pionERA) in 1L ER+/HER2- MBC
Giredestrant (lidERA) in adjuvant ER+ BC
Giredestrant + Phesgo (heredERA) in 1L maint ER+/HER2+
Inavolisib + palbo + fulv (INAVO120) in 1L HR+/HER2-/PI3Km MBC
Inavolisib + fulv (INAVO121) post CDK4/6i HR+/HER2-/PI3Km BC
Inavolisib + Phesgo (INAVO122) in 1L HER2+/PI3Km BC
Unknown
TNBC
HR-/HER2+
HR+/HER2-
HR+/HER2+
Further potential to grow our breast cancer franchise:
Expanding into HR+ with two NMEs in Ph III, including in combination with Phesgo
1 Cancer Stats Facts: Female Breast Cancer Subtypes. National Cancer institute. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html (Access date: May 24, 2022; HER2-Human Epidermal growth
factor Receptor 2; HR=Hormone receptor; TNBC-Triple negative breast cancer; SERD=Selective estrogen receptor degrader; ER-Estrogen receptor; PI3K-Phosphoinositide 3-Kinase; TKI-Tyrosine kinase inhibitor
Roche
55View entire presentation